Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.

Abstract

Irinotecan (CPT-11, Camptosar) has significant activity in small-cell lung cancer. In addition, preclinical models have demonstrated synergy between irinotecan and two standard front-line drugs for small-cell lung cancer: cisplatin and etoposide; phase III data also show significant survival benefit for irinotecan/cisplatin compared to standard treatment. These data suggest a potential clinical advantage to combining etoposide, cisplatin, and irinotecan as first-line therapy for small-cell lung cancer. The purpose of this phase I study was to establish if alternating weekly therapy with irinotecan/cisplatin and etoposide/cisplatin was tolerated and to determine the maximum tolerated dose of these agents in patients with small-cell lung cancer. Patients generally tolerated the weekly alternating chemotherapy with irinotecan/cisplatin and etoposide/cisplatin well, and this combination possessed significant antitumor activity in small-cell lung cancer.

• Authors: Faye M Johnson, Jonathan M Kurie, Beverly O Peeples, Katherine M Pisters, Frank V Fossella, Vassiliki A Papadimitrakopoulou, George R Blumenschein, Ritsuko Komaki, Bonnie S Glisson
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 17 Issue 7 Suppl 7 Pg. 17-21 (Jul 2003) ISSN: 0890-9091 [Print] United States
• PMID: 12886869 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)

Chemical References

• Etoposide
• Irinotecan
• Cisplatin
• Camptothecin

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
• Camptothecin (administration & dosage, adverse effects, analogs & derivatives)
• Carcinoma, Small Cell (drug therapy)
• Cisplatin (administration & dosage, adverse effects)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Etoposide (administration & dosage, adverse effects)
• Female
• Humans
• Irinotecan
• Lung Neoplasms (drug therapy)
• Male
• Maximum Tolerated Dose
• Middle Aged
• Treatment Outcome